Olaparib Treatment in a Patient with Advanced Gallbladder Cancer Harboring BRCA1 Mutation

Abstract

Xiaofen Li,1 Limin Gao,2 Meng Qiu,1 Dan Cao1 1Department of Abdominal Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of China; 2Department of Pathology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of ChinaCorrespondence: Dan Cao; Meng QiuDepartment of Abdominal Oncology, West China Hospital, Sichuan University, Chengdu, Sichuan, People’s Republic of ChinaTel [phone]Fax [phone]Email [email protected]; [email protected]: Gallbladder cancer is a highly aggressive malignancy with an extremely poor prognosis. Germline BRCA1 mutation in gallbladder cancer is very rare. Herein, we present a case of a 73-year-old Asian patient diagnosed with lymph nodes and peritoneal metastases just two months after surgery for primary gallbladder cancer. The patient had a past history of early-stage breast cancer and received a left radical mastectomy 27 years ago. Next-generation sequencing (NGS) was performed as the patient refused to receive systemic chemotherapy. According to NGS result of germline BRCA1 mutation, the patient was administered first-line Olaparib and obtained a progression-free survival of about 6 months. Furthermore, we briefly summarized the current targeted treatment of gallbladder cancer. To the best of our knowledge, this is the first report of germline BRCA1 p. S451Lfs*20 mutation and first-line Olaparib treatment in a metastatic gallbladder cancer patient. As a highly heterogeneous and aggressive malignancy, we suggest making clinical decisions according to a precision medicine concept based on gene sequencing in advanced gallbladder cancer.Keywords: gallbladder cancer, BRCA1 mutation, Olaparib

Keywords

• gallbladder cancer
• brca1 mutation
• olaparib